DocMorris Beheer

Beheer criteriumcontroles 2/4

De CEO DocMorris is Walter Hess, benoemd in Apr2022, heeft een ambtstermijn van 2.58 jaar. De totale jaarlijkse vergoeding van { bedraagt CHF 1.84M, bestaande uit 38.1% salaris en 61.9% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.28% van de aandelen van het bedrijf, ter waarde CHF 1.08M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 2.6 jaar en 5.5 jaar.

Belangrijke informatie

Walter Hess

Algemeen directeur

CHF 1.8m

Totale compensatie

Percentage CEO-salaris	38.1%
Dienstverband CEO	2.6yrs
Eigendom CEO	0.3%
Management gemiddelde ambtstermijn	2.6yrs
Gemiddelde ambtstermijn bestuur	5.5yrs

Recente managementupdates

Recent updates

Earnings Update: Zur Rose Group AG (VTX:ROSE) Just Reported And Analysts Are Trimming Their Forecasts

Mar 22

Some Zur Rose Group AG (VTX:ROSE) Analysts Just Made A Major Cut To Next Year's Estimates

Mar 20

What Kind Of Investors Own Most Of Zur Rose Group AG (VTX:ROSE)?

Feb 23

Is Zur Rose Group's (VTX:ROSE) Share Price Gain Of 210% Well Earned?

Jan 19

Zur Rose Group AG (VTX:ROSE) Is Expected To Breakeven In The Near Future

Dec 15

Analyse CEO-vergoeding

Hoe is Walter Hess's beloning veranderd ten opzichte van DocMorris's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	-CHF 97m
Mar 31 2024	n/a	n/a	-CHF 107m
Dec 31 2023	CHF 2m	CHF 700k	-CHF 118m
Sep 30 2023	n/a	n/a	-CHF 132m
Jun 30 2023	n/a	n/a	-CHF 146m
Mar 31 2023	n/a	n/a	-CHF 158m
Dec 31 2022	CHF 1m	CHF 617k	-CHF 171m

Compensatie versus markt: De totale vergoeding ($USD 2.05M ) Walter } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de Swiss markt ($USD 1.21M ).

Compensatie versus inkomsten: De vergoeding van Walter is gestegen terwijl het bedrijf verliesgevend is.

CEO

Walter Hess (59 yo)

2.6yrs

Tenure

CHF 1,837,000

Compensatie

Mr. Walter Hess had been Head of Germany at Zur Rose Group AG since December 10, 2020 until April 28, 2022 and serves as its Member of Executive Board and serves as its Chief Executive Officer since April...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Walter Oberhansli	Founder & Chairman	31.8yrs	CHF 432.00k	0.90% CHF 3.4m
Walter Hess	CEO & Member of Executive Board	2.6yrs	CHF 1.84m	0.28% CHF 1.1m
Daniel Wüest	CFO & Member of Executive Board	less than a year	geen gegevens	geen gegevens
David Maso	Head of Europe & Member of Executive Board	4.5yrs	geen gegevens	0.28% CHF 1.0m
Madhu Nutakki	CTO & Member of Executive Board	3.3yrs	geen gegevens	geen gegevens
Kaspar Niklaus	COO & Member of Executive Board	2yrs	geen gegevens	0.0041% CHF 15.7k
Daniel Grigat	Group Head of Investor Relations & Sustainability	no data	geen gegevens	geen gegevens
Torben Bonnke	Director of Communications	no data	geen gegevens	geen gegevens

2.6yrs

Gemiddelde duur

55yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van DOCM wordt beschouwd als ervaren (gemiddelde ambtstermijn 2.6 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Walter Oberhansli	Founder & Chairman	31.8yrs	CHF 432.00k	0.90% CHF 3.4m
Florian Seubert	Non-Executive Independent Director	5.5yrs	CHF 149.00k	0.030% CHF 115.3k
Stefan Feuerstein	Independent Vice Chairman of the Board	14.8yrs	CHF 217.00k	0.42% CHF 1.6m
Christian Mielsch	Non-Executive Independent Director	5.5yrs	CHF 183.00k	0.085% CHF 324.6k
Andrea Belliger	Non-Executive Independent Director	3.6yrs	CHF 167.00k	0.024% CHF 90.6k
Rongrong Hu	Non-Executive Independent Director	2.6yrs	CHF 164.00k	0.023% CHF 88.9k

5.5yrs

Gemiddelde duur

58yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van DOCM wordt beschouwd als ervaren (gemiddelde ambtstermijn 5.5 jaar).

DocMorris Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Zur Rose Group AG, Annual General Meeting, May 04, 2023

Zur Rose Group AG Announces Resignation of Betül Susamis Unaran, Chief Strategy and Digital Officer and as Member of the Executive Board

Zur Rose Group AG Announces Management Changes

Recent updates

DocMorris AG's (VTX:DOCM) Subdued P/S Might Signal An Opportunity

Price target decreased by 9.9% to CHF60.50

Does DocMorris (VTX:DOCM) Have A Healthy Balance Sheet?

Price target decreased by 9.1% to CHF70.92

No longer forecast to breakeven

First half 2024 earnings released: CHF3.22 loss per share (vs CHF4.99 loss in 1H 2023)

New minor risk - Profitability

Price target decreased by 10% to CHF88.50

DocMorris AG to Report First Half, 2025 Results on Aug 19, 2025

DocMorris AG to Report Q3, 2025 Results on Oct 16, 2025

New minor risk - Shareholder dilution

Price target increased by 7.5% to CHF99.24

Price target increased by 7.4% to CHF95.49

Full year 2023 earnings released: CHF10.07 loss per share (vs CHF15.88 loss in FY 2022)

Price target increased by 7.2% to CHF85.27

Price target increased by 7.9% to CHF84.09

Consensus EPS estimates fall by 27%

Consensus EPS estimates upgraded to CHF4.58 loss

Price target increased by 8.7% to CHF75.00

Price target increased by 12% to CHF72.33

Price target increased by 9.1% to CHF69.00

Consensus EPS estimates fall by 11%

Consensus EPS estimates upgraded to CHF3.46 loss

New minor risk - Profitability

DocMorris AG to Report Fiscal Year 2023 Results on Mar 21, 2024

Price target increased by 10% to CHF64.86

Consensus EPS estimates upgraded to CHF3.21 loss, revenue downgraded

Price target increased by 10% to CHF57.33

First half 2023 earnings released: CHF4.99 loss per share (vs CHF8.05 loss in 1H 2022)

Medbase AG acquired Swiss business of Zur Rose from Zur Rose Group AG (SWX:ROSE).

Medbase AG acquired Swiss business of Zur Rose from Zur Rose Group AG (SWX:ROSE).

Price target decreased by 30% to CHF37.96

Price target decreased to CHF73.14

Price target decreased to CHF78.73

Reade Griffith acquired an unknown minority stake in Zur Rose Group AG (SWX:ROSE).

Would Zur Rose Group (VTX:ROSE) Be Better Off With Less Debt?

Price target decreased to CHF107

First half 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased to CHF134

Zur Rose Group AG, Annual General Meeting, May 04, 2023

Price target decreased to CHF154

Zur Rose Group AG Announces Resignation of Betül Susamis Unaran, Chief Strategy and Digital Officer and as Member of the Executive Board

Price target decreased to CHF197

Zur Rose Group AG to Report First Half, 2022 Results on Aug 18, 2022

Price target decreased to CHF281

Price target decreased to CHF303

Consensus forecasts updated

Price target decreased to CHF387

Price target decreased to CHF404

No longer forecast to breakeven

We Think Zur Rose Group (VTX:ROSE) Has A Fair Chunk Of Debt

We Think Zur Rose Group (VTX:ROSE) Has A Fair Chunk Of Debt

First half 2021 earnings released: CHF8.03 loss per share (vs CHF6.03 loss in 1H 2020)

Consensus forecasts updated

No longer forecast to breakeven

No longer forecast to breakeven

Non-Executive Director has left the company

Is Zur Rose Group (VTX:ROSE) Using Too Much Debt?

Full year 2020 earnings released: CHF14.95 loss per share (vs CHF6.04 loss in FY 2019)

Earnings Update: Zur Rose Group AG (VTX:ROSE) Just Reported And Analysts Are Trimming Their Forecasts

Full year 2020 earnings released

Some Zur Rose Group AG (VTX:ROSE) Analysts Just Made A Major Cut To Next Year's Estimates

Zur Rose Group AG Provides Earnings Guidance for the Year 2021

What Kind Of Investors Own Most Of Zur Rose Group AG (VTX:ROSE)?

Price target raised to CHF453

New 90-day high: CHF476

Price target raised to CHF400

Zur Rose Group AG to Report First Half, 2021 Results on Aug 19, 2021

Is Zur Rose Group's (VTX:ROSE) Share Price Gain Of 210% Well Earned?

New 90-day high: CHF380

Zur Rose Group Announces Collaboration with Novo Nordisk

New 90-day high: CHF283